Sun Pharma (SUNPHARMA): Latest Business Update & 5-Quarter Financial Performance

Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) remains one of the major pharmaceutical companies from India, with businesses spanning branded formulations, generics, innovative medicines and consumer healthcare. The company operates across more than 100 countries and has been increasing its focus on specialty/innovative medicines alongside its established India and US businesses.

Sun Pharma: What is happening now?

The latest reported quarter is Q1 FY27, ended June 30, 2026. Sun Pharma reported consolidated sales of ₹15,183.6 crore, up 10.1% YoY. Reported net profit was ₹2,894.8 crore, while adjusted net profit was ₹3,089.4 crore, up 3.1% YoY. EBITDA stood at ₹4,417.7 crore, with an EBITDA margin of 28.9%.

One of the important growth areas was India formulations, where sales increased 16% to ₹5,474.9 crore. Sun Pharma's India market share increased to 8.5% from 8.2%, according to the company's cited Pharmarack MAT June 2026 data.

The Global Innovative Medicines business also continued to expand. Q1 FY27 sales were US$351 million, up 12.8%, representing 21.9% of total sales. However, US formulation sales were US$427 million, down 9.7%, with growth in innovative medicines partly offsetting weakness in generics.

A major development: Organon acquisition

Sun Pharma announced an agreement in April 2026 to acquire 100% of Organon for $14 per share, representing an equity value of approximately $3.99 billion and enterprise value of about $11.75 billion. The transaction is expected to close in early 2027, subject to regulatory and other customary conditions.

The proposed transaction would significantly increase Sun Pharma's international scale, but it also involves additional financing and therefore will change the company's balance-sheet profile. Sun Pharma management has indicated that post-transaction net debt/EBITDA is expected to be around 2.3x.

Latest US development

In September 2026, Sun Pharma also participated in a US pharmaceutical pricing agreement involving Most-Favoured-Nation (MFN) pricing. The US government said the agreement includes Sun Pharma and other pharmaceutical companies; Sun Pharma's participation involves MFN pricing for certain medicines, including future innovative launches, alongside other commitments.

For investors, this is relevant because the US is an important part of Sun Pharma's business, while the exact financial impact of the agreement is not publicly quantified in the sources reviewed.

📊 Sun Pharma – Last 5 Reported Quarters

Quarter	Sales / Revenue	YoY Growth	Net Profit	YoY Growth
Q1 FY27	₹15,183.6 Cr	+10.1%	₹2,894.8 Cr	—
Q4 FY26	₹14,559.8 Cr	+13.6%	₹2,714.0 Cr	+26.2%
Q3 FY26	₹15,469.1 Cr	+15.1%	₹3,368.8 Cr	+16.0%
Q2 FY26	₹14,405.2 Cr	+8.6%	₹3,118.0 Cr	+2.6%
Q1 FY26	₹13,786.1 Cr	+10.1%	₹2,278.6 Cr*	—

*Q1 FY26 reported profit was affected by exceptional items; adjusted net profit was ₹2,996.1 crore, up 5.7%.

Q2 FY26 sales were ₹14,405.2 crore with EBITDA of ₹4,527.1 crore and net profit of ₹3,118 crore. Q3 FY26 sales reached ₹15,469.1 crore and net profit ₹3,368.8 crore. Q4 FY26 sales were ₹14,559.8 crore and net profit ₹2,714 crore.

📈 What the 5-quarter numbers show

Over these five quarters, quarterly sales have generally remained in the ₹13,700–₹15,500 crore range, with Q3 FY26 recording the highest sales in this period at ₹15,469 crore. The latest Q1 FY27 quarter showed another year-on-year sales increase, led particularly by India formulations and Innovative Medicines.

The company is also continuing to invest heavily in R&D. In Q1 FY27, R&D expenditure was ₹826.4 crore, equal to 5.4% of sales. Its pipeline includes candidates in areas such as psoriasis, cancer, diabetes and other conditions.

Key things to watch going forward

1. Organon acquisition – regulatory approvals, financing and integration will be important developments through 2026–27.

2. US business – US formulation sales declined 9.7% in Q1 FY27, making the recovery of the generics business an important quarterly metric.

3. Innovative Medicines – Q1 FY27 sales grew 12.8% to US$351 million, making this an increasingly significant part of Sun Pharma's portfolio.

4. India growth – India formulation sales grew 16% in Q1 FY27, with the company's reported market share reaching 8.5%.

5. Debt and cash flow after Organon – the proposed transaction is substantially larger than Sun Pharma's previous acquisitions, so investors will be watching leverage and cash generation after completion.

Final takeaway

Sun Pharma's recent financial performance shows continued revenue growth, strong India business and expanding Innovative Medicines sales, while the US generics business remains an area to monitor. The proposed Organon acquisition could materially change the company's global scale and financial structure once completed. The next major focus will therefore be the execution of the Organon transaction, US business performance and growth of the innovative-medicine portfolio. These are factual business factors to monitor rather than a prediction about the stock's future performance.

Sources: Sun Pharma's official quarterly results, investor materials and regulatory disclosures, supplemented by current reporting on the US pricing agreement.

1. The real Sun Pharma story

Sun Pharma is no longer simply an Indian generic-drug company.

Its business has gradually moved toward a combination of:

🇮🇳 India branded formulations
🇺🇸 US generics
💊 Specialty / innovative medicines
🌍 Emerging markets
🧪 R&D and complex products
🤝 Large international acquisitions

This transformation is important because specialty medicines generally have different economics from traditional commodity generics.

In Q1 FY27, Sun Pharma's India formulations grew 16% YoY to ₹5,474.9 crore, while Global Innovative Medicines grew 12.9% to US$351 million. At the same time, US formulations declined 9.7% to US$427 million.

So the current picture is not simply "everything is growing." The growth engines are different across geographies.

2. Business mix — this is what investors should watch

Q1 FY27 sales

Segment	Q1 FY27	YoY
🇮🇳 India Formulations	₹5,474.9 Cr	+16%
🇺🇸 US Formulations	₹4,041.9 Cr*	—
🌎 Emerging Markets	₹2,945.6 Cr*	—
🌍 Rest of World	₹2,068.6 Cr*	—
🧪 API	₹597.2 Cr	+10.5%
Total Sales	₹15,183.6 Cr	+10.1%

*Converted from reported segment figures in ₹ lakh; the company's reporting uses USD for several international segments.

The important point

India + Innovative Medicines are currently doing much of the heavy lifting.

The US generics business is a different story and needs monitoring.

3. Why specialty medicines matter so much

This is one of the most important things to understand about Sun Pharma.

Traditional generic medicines can face:

More competitors → price pressure → lower margins.

Specialty medicines can potentially offer:

Higher differentiation → stronger pricing power → longer product economics.

Sun Pharma has built a significant specialty portfolio, particularly around areas such as:

Dermatology
Ophthalmology
Oncology
Immunology
Neurology

The company reported US$351 million of Global Innovative Medicines sales in Q1 FY27, representing approximately 21.9% of total sales.

This is strategically important because Sun Pharma wants a larger proportion of its business to come from differentiated products rather than relying exclusively on conventional generics.

4. The Organon acquisition changes the story

This is probably the single biggest strategic development for Sun Pharma right now.

Sun Pharma agreed to acquire Organon for $14 per share, with an enterprise value of approximately $11.75 billion.

The transaction is expected to close in early 2027, subject to required conditions and regulatory approvals. Organon shareholders approved the transaction in July 2026.

Why does Organon matter?

Organon reported approximately:

$6.2 billion revenue in 2025
$1.9 billion adjusted EBITDA
$8.6 billion debt
$574 million cash

according to the transaction announcement.

This means Sun Pharma is effectively taking on a much larger international business along with significant debt.

The opportunity

Sun Pharma says the combination should create:

Larger global scale + broader portfolio + additional cash generation + potential synergies.

But here is the key risk

The acquisition isn't free.

Sun Pharma has said post-transaction net debt/EBITDA could be around 2.3×.

Before the deal, Sun Pharma's balance sheet was considerably stronger.

Therefore, after the acquisition, investors should watch:

Debt reduction → cash flow → integration → synergies → earnings growth

rather than simply looking at the headline increase in revenue.

5. The hidden strength: cash generation

A pharmaceutical company can report strong accounting profit but still have poor cash generation.

Sun Pharma has historically generated substantial free cash flow.

FY26 free cash flow was approximately ₹8,810 crore, compared with ₹11,944 crore in FY25.

The decline doesn't automatically indicate a structural problem; working-capital movements, taxes and investment levels can affect annual free cash flow.

But after Organon, cash generation becomes much more important.

Why?

Because Sun Pharma needs cash to:

Fund R&D
Pay dividends
Invest in manufacturing
Make acquisitions
Reduce acquisition-related debt

6. Profit quality — don't look only at headline PAT

Q1 FY27 reported PAT:

₹2,894.8 crore

That represents approximately 27% YoY growth.

Sounds excellent.

But there is an important detail.

Adjusted PAT was approximately:

₹3,089.4 crore

and grew only around 3.1% YoY.

Why the difference?

The previous year's quarter had substantially higher exceptional charges.

Q1 FY27 also included approximately ₹204 crore of exceptional expenses, including costs associated with the Organon transaction.

Therefore:

Headline PAT growth ≠ underlying operating profit growth.

For serious analysis, I would pay more attention to:

Adjusted PAT + EBITDA + operating cash flow + specialty growth.

7. Margin picture

Q1 FY27 EBITDA:

₹4,417.7 crore

EBITDA grew approximately 2.7% YoY.

But EBITDA margin fell from approximately 31.1% to 28.9%.

This is something investors should watch.

Revenue:

↑ 10.5%

EBITDA:

↑ 2.7%

Therefore, operating profit isn't growing as quickly as revenue.

The next few quarters will tell us whether this is temporary or represents a more persistent margin issue.

8. R&D — one of the most important future indicators

Sun Pharma spent approximately:

₹826 crore on R&D in Q1 FY27

That represented about 5.4% of sales.

This is important because pharmaceutical companies ultimately depend on their product pipeline.

Today's revenue comes from existing products.

Tomorrow's revenue comes from:

Pipeline → clinical development → regulatory approval → commercial launch → market adoption.

Therefore, investors shouldn't only ask:

"How much profit did Sun Pharma make?"

They should also ask:

"What products can generate the next wave of revenue?"

9. GLP-1 opportunity

Another interesting development is the company's entry into the semaglutide/GLP-1 opportunity.

Sun Pharma received approval in Brazil to manufacture and market generic semaglutide and also received approval for generic semaglutide in South Africa in July 2026.

This is an area worth monitoring because GLP-1 medicines have become a major global pharmaceutical category.

But it is important not to assume that regulatory approval automatically translates into a large profit contribution. Actual commercial performance will depend on:

Launch timing
Pricing
Competition
Market access
Manufacturing capacity
Regulatory conditions

10. US business — the biggest area to watch

The US remains a major part of Sun Pharma.

But Q1 FY27 US formulation sales fell 9.7% to US$427 million.

The company attributed part of the weakness to the generics business, including lenalidomide.

This creates an interesting contrast:

India

Strong growth

Innovative medicines

Strong growth

US generics

Weakness

Therefore, the next few quarterly results should be examined for whether US generics stabilise.

11. Regulatory risk

Pharma investors need to think differently from investors in companies such as banks or FMCG companies.

One FDA issue can potentially affect:

Production
Exports
Product approvals
Supply
Revenue
Margins

So for Sun Pharma, USFDA observations, manufacturing-site status and product approvals deserve regular monitoring.

The company has also recently received favourable developments concerning long-running US litigation.

In August 2026, the US Court of Appeals for the Third Circuit affirmed a lower-court judgment in the Lipitor antitrust litigation.

And in September 2026, Sun Pharma's US subsidiaries entered into a settlement in another generic-drug pricing antitrust litigation; the settlement amount was confidential and the agreement included no admission of wrongdoing.

These developments reduce some historical legal uncertainty, although they don't eliminate regulatory/business risks.

12. Valuation — this is where the story becomes interesting

As of the 18 September 2026 close, Sun Pharma was around ₹1,835.50 and roughly 10% below its 52-week high of ₹2,047.55.

Another market-data source reported market capitalisation around ₹4.4 lakh crore.

But there is an important data-quality point:

Different financial websites currently display very different P/E figures, depending on whether they use standalone/consolidated data and how exceptional items and trailing earnings are treated. For example, one source currently shows a trailing P/E above 130×, while another consolidated-data source shows roughly 37×.

So don't blindly copy a P/E from a stock website.

For your blog, I recommend writing:

"Sun Pharma trades at a premium valuation, and investors should evaluate the multiple using normalized consolidated earnings rather than relying on a single website's headline P/E."

That is much more accurate.

13. What could drive the next 3–5 years?

Here is the real investment framework I would use to track SUNPHARMA:

Growth engines

① India formulations

Large branded portfolio + chronic therapies + market leadership.

② Specialty medicines

Potentially higher-value products and increasing contribution.

③ Organon

Potentially transforms Sun Pharma's global scale.

④ GLP-1

Semaglutide could become an additional growth opportunity.

⑤ Product pipeline

New launches and approvals can create incremental revenue.

⑥ Emerging markets

Provides geographic diversification.

14. What could go wrong?

This part is equally important.

Risk 1 — Organon debt

The acquisition substantially changes the balance sheet.

Risk 2 — Integration

Buying a company is easier than successfully integrating it.

Risk 3 — US generics

Pricing pressure and competition can hurt sales.

Risk 4 — FDA/regulatory issues

Manufacturing or regulatory problems can affect products.

Risk 5 — Specialty-product concentration

A large specialty portfolio also means dependence on the success and lifecycle of particular products.

Risk 6 — Valuation

Even a good company can deliver disappointing stock returns if investors pay too high a valuation.

Risk 7 — Margin pressure

Q1 FY27 EBITDA margin declined to 28.9%.

15. The 5 numbers I would track every quarter

If you're writing regular Finance Facts PR articles on SUNPHARMA, don't track 20 numbers.

Track these five:

Metric	Why it matters
India sales growth	Measures domestic engine
Innovative medicine sales	Measures specialty transformation
US sales	Measures international performance
EBITDA margin	Measures profitability
Net debt / cash flow	Critical after Organon

This gives a much better picture than simply saying:

"Profit increased 27%."

16. My "investor dashboard" for SUNPHARMA

🟢 Growth to monitor

India + Specialty + New products

🟡 Watch carefully

US generics + EBITDA margin

🟠 Major strategic event

Organon acquisition

🔴 Major risk

Debt + integration + regulatory issues

💰 Cash-flow focus

Free cash flow + debt reduction after acquisition

🧪 Long-term engine

R&D + specialty pipeline + complex products

17. The biggest question for SUNPHARMA

The most important question isn't:

"Will Sun Pharma's profit rise next quarter?"

A better question is:

"Can Sun Pharma successfully convert its strong India franchise and specialty portfolio into a much larger global pharmaceutical platform while integrating Organon and controlling the additional debt?"

That is the central story investors should follow through FY27–FY29.

Sun Pharma's own transaction materials describe the Organon combination as a move toward greater global scale and indicate that EBITDA and cash flow are expected to nearly double, while also highlighting post-transaction leverage of around 2.3× net debt/EBITDA.

That makes Organon both the company's biggest opportunity and one of the most important execution variables.

📌 Blog-ready conclusion

Sun Pharma is entering an important transition period. The company continues to show strong momentum in India and innovative medicines, while the US generics business remains an area to monitor. The proposed Organon acquisition could significantly increase Sun Pharma's global scale and cash-generation capacity, but it also introduces additional leverage and integration requirements. Meanwhile, its R&D pipeline, specialty medicines and GLP-1 opportunity provide potential future growth avenues.

For investors, the next few quarters should be watched through five lenses: India growth, specialty-medicine growth, US recovery, EBITDA margins and post-Organon debt/cash flow. These indicators will provide a clearer picture of whether Sun Pharma is successfully executing its next phase of expansion.

This is an analytical framework, not a buy/sell recommendation.

📊 Current snapshot

Latest reported quarter: Q1 FY27
Revenue from operations: ₹15,299.9 Cr
Sales excluding other operating revenue: ₹15,183.6 Cr
Reported PAT: ₹2,894.8 Cr
Adjusted PAT: ₹3,089.4 Cr
EBITDA: ₹4,417.7 Cr
EBITDA margin: 28.9%
India formulation growth: 16%
Innovative Medicines growth: 12.9%
US formulation growth: -9.7%
R&D: ₹826.4 Cr
Organon transaction: $11.75B enterprise value
Expected Organon closure: early 2027, subject to conditions

ads

ads

Sun Pharma (SUNPHARMA) Latest Update: Q1 FY27 Results, Organon Deal & 5-Quarter Financial Analysis